Key result
EACAB within 180 days of DES for ACS shows ~17% MACCE incidence.
Why the study?
Evidence on performing minimally invasive coronary artery surgery early after drug-eluting stent implantation for acute coronary syndrome was limited.
Does endoscopic atraumatic coronary artery bypass (EACAB) surgery prevent major adverse cardiac and cerebrovascular events in patients who recently received a drug-eluting stent for acute coronary syndrome?
Observational (n=115)
No
Does endoscopic atraumatic coronary artery bypass (EACAB) surgery prevent major adverse cardiac and cerebrovascular events in patients who recently received a drug-eluting stent for acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Endoscopic atraumatic coronary artery bypass (EACAB) is a safe and feasible method for LAD revascularization in patients who recently received a DES for ACS, demonstrating an acceptable 17.4% MACCE rate at 3.7 years despite early dual antiplatelet therapy discontinuation.
BACKGROUND: The evidence on performing minimally invasive coronary artery surgery early after drug-eluting stent (DES) implantation due to acute coronary syndrome (ACS) is limited. AIM: The study aimed to determine the safety and feasibility of this approach. METHODS: This registry included 115 (78% male) patients treated from 2013 to 2018, who underwent non-left anterior descending (LAD) percutaneous coronary intervention (PCI) due to ACS with contemporary DES implantation (39% diagnosed with myocardial infarction at baseline), followed by endoscopic atraumatic coronary artery bypass (EACAB) surgery within 180 days, after temporary P2Y12 inhibitor discontinuation. Primary composite endpoint of MACCE (major adverse cardiac and cerebrovascular events), defined as death, myocardial infarction (MI), cerebrovascular incident, and repeat revascularization was evaluated in long-term follow-up. The follow-up was collected via a telephone survey and in line with National Registry for Cardiac Surgery Procedures. RESULTS: The median (interquartile range [IQR]) time interval separating both procedures was 100.0 (62.0-136.0) days. Median (IQR) follow-up duration was 1338.5 (753.0-2093.0) days and was completed for all patients with regard to mortality. Eight patients (7%) died; 2 (1.7%) had a stroke; 6 (5.2%) suffered from MI, and 12 (10.4%) required repeat revascularization. Overall, the incidence of MACCE was 20 (17.4%). CONCLUSIONS: EACAB is a safe and feasible method of LAD revascularization in patients who received DES for ACS within 180 days before surgery despite early dual antiplatelet therapy discontinuation. The adverse event rate is low and acceptable.
No takes yet. Share an insight, caveat, or question.
Sanetra et al. (2023) conducted an observational in Acute coronary syndrome (n=115). Endoscopic atraumatic coronary artery bypass (EACAB) was evaluated on Composite of MACCE (death, myocardial infarction, cerebrovascular incident, and repeat revascularization). Endoscopic atraumatic coronary artery bypass (EACAB) performed within 180 days after drug-eluting stent implantation for acute coronary syndrome was associated with a 17.4% incidence of MACCE over a median follow-up of 3.7 years.
Synapse has enriched 10 related papers. Consider them for comparative context: